vs
AdvanSix Inc.（ASIX）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
AdvanSix Inc.的季度营收约是Orthofix Medical Inc.的1.6倍（$359.9M vs $219.9M），AdvanSix Inc.净利率更高（-0.8% vs -1.0%，领先0.2%），AdvanSix Inc.同比增速更快（9.4% vs 2.0%），AdvanSix Inc.自由现金流更多（$36.1M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 3.4%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ASIX vs OFIX — 直观对比
营收规模更大
ASIX
是对方的1.6倍
$219.9M
营收增速更快
ASIX
高出7.4%
2.0%
净利率更高
ASIX
高出0.2%
-1.0%
自由现金流更多
ASIX
多$19.3M
$16.8M
两年增速更快
OFIX
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $219.9M |
| 净利润 | $-2.8M | $-2.2M |
| 毛利率 | 7.6% | 71.1% |
| 营业利润率 | -0.7% | 0.2% |
| 净利率 | -0.8% | -1.0% |
| 营收同比 | 9.4% | 2.0% |
| 净利润同比 | -892.9% | 92.4% |
| 每股收益（稀释后） | $-0.11 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXOFIX
| Q4 25 | $359.9M | $219.9M | ||
| Q3 25 | $374.5M | $205.6M | ||
| Q2 25 | $410.0M | $203.1M | ||
| Q1 25 | $377.8M | $193.6M | ||
| Q4 24 | $329.1M | $215.7M | ||
| Q3 24 | $398.2M | $196.6M | ||
| Q2 24 | $453.5M | $198.6M | ||
| Q1 24 | $336.8M | $188.6M |
净利润ASIXOFIX
| Q4 25 | $-2.8M | $-2.2M | ||
| Q3 25 | $-2.6M | $-22.8M | ||
| Q2 25 | $31.4M | $-14.1M | ||
| Q1 25 | $23.3M | $-53.1M | ||
| Q4 24 | $352.0K | $-29.1M | ||
| Q3 24 | $22.3M | $-27.4M | ||
| Q2 24 | $38.9M | $-33.4M | ||
| Q1 24 | $-17.4M | $-36.0M |
毛利率ASIXOFIX
| Q4 25 | 7.6% | 71.1% | ||
| Q3 25 | 6.8% | 72.2% | ||
| Q2 25 | 14.3% | 68.7% | ||
| Q1 25 | 14.2% | 62.8% | ||
| Q4 24 | 3.4% | 69.0% | ||
| Q3 24 | 14.4% | 68.7% | ||
| Q2 24 | 17.9% | 67.8% | ||
| Q1 24 | 0.9% | 67.5% |
营业利润率ASIXOFIX
| Q4 25 | -0.7% | 0.2% | ||
| Q3 25 | -0.9% | -8.3% | ||
| Q2 25 | 7.7% | -7.9% | ||
| Q1 25 | 7.7% | -25.2% | ||
| Q4 24 | -3.9% | -5.3% | ||
| Q3 24 | 7.5% | -9.6% | ||
| Q2 24 | 11.5% | -12.5% | ||
| Q1 24 | -7.0% | -15.6% |
净利率ASIXOFIX
| Q4 25 | -0.8% | -1.0% | ||
| Q3 25 | -0.7% | -11.1% | ||
| Q2 25 | 7.7% | -6.9% | ||
| Q1 25 | 6.2% | -27.4% | ||
| Q4 24 | 0.1% | -13.5% | ||
| Q3 24 | 5.6% | -13.9% | ||
| Q2 24 | 8.6% | -16.8% | ||
| Q1 24 | -5.2% | -19.1% |
每股收益（稀释后）ASIXOFIX
| Q4 25 | $-0.11 | $-0.05 | ||
| Q3 25 | $-0.10 | $-0.57 | ||
| Q2 25 | $1.15 | $-0.36 | ||
| Q1 25 | $0.86 | $-1.35 | ||
| Q4 24 | $0.02 | $-0.76 | ||
| Q3 24 | $0.82 | $-0.71 | ||
| Q2 24 | $1.43 | $-0.88 | ||
| Q1 24 | $-0.65 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $815.2M | $450.0M |
| 总资产 | $1.7B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASIXOFIX
| Q4 25 | $19.8M | $82.0M | ||
| Q3 25 | $23.7M | $62.9M | ||
| Q2 25 | $18.4M | $65.6M | ||
| Q1 25 | $8.3M | $58.0M | ||
| Q4 24 | $19.6M | $83.2M | ||
| Q3 24 | $17.3M | $30.1M | ||
| Q2 24 | $12.1M | $26.4M | ||
| Q1 24 | $20.6M | $27.0M |
总债务ASIXOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益ASIXOFIX
| Q4 25 | $815.2M | $450.0M | ||
| Q3 25 | $818.2M | $442.5M | ||
| Q2 25 | $823.7M | $458.3M | ||
| Q1 25 | $794.4M | $458.3M | ||
| Q4 24 | $774.6M | $503.1M | ||
| Q3 24 | $766.4M | $525.9M | ||
| Q2 24 | $746.6M | $546.0M | ||
| Q1 24 | $713.2M | $570.3M |
总资产ASIXOFIX
| Q4 25 | $1.7B | $850.6M | ||
| Q3 25 | $1.7B | $832.6M | ||
| Q2 25 | $1.6B | $837.2M | ||
| Q1 25 | $1.6B | $823.1M | ||
| Q4 24 | $1.6B | $893.3M | ||
| Q3 24 | $1.5B | $867.9M | ||
| Q2 24 | $1.5B | $882.0M | ||
| Q1 24 | $1.5B | $906.0M |
负债/权益比ASIXOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $36.1M | $16.8M |
| 自由现金流率自由现金流/营收 | 10.0% | 7.6% |
| 资本支出强度资本支出/营收 | 7.7% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $6.4M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ASIXOFIX
| Q4 25 | $63.7M | $27.7M | ||
| Q3 25 | $26.6M | $12.4M | ||
| Q2 25 | $21.1M | $11.6M | ||
| Q1 25 | $11.4M | $-18.4M | ||
| Q4 24 | $64.2M | $23.7M | ||
| Q3 24 | $57.3M | $11.7M | ||
| Q2 24 | $50.2M | $9.0M | ||
| Q1 24 | $-36.2M | $-18.6M |
自由现金流ASIXOFIX
| Q4 25 | $36.1M | $16.8M | ||
| Q3 25 | $66.0K | $2.5M | ||
| Q2 25 | $-7.2M | $4.5M | ||
| Q1 25 | $-22.6M | $-25.1M | ||
| Q4 24 | $29.8M | $15.2M | ||
| Q3 24 | $26.8M | $6.3M | ||
| Q2 24 | $16.7M | $-360.0K | ||
| Q1 24 | $-71.6M | $-29.1M |
自由现金流率ASIXOFIX
| Q4 25 | 10.0% | 7.6% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | -1.7% | 2.2% | ||
| Q1 25 | -6.0% | -13.0% | ||
| Q4 24 | 9.1% | 7.0% | ||
| Q3 24 | 6.7% | 3.2% | ||
| Q2 24 | 3.7% | -0.2% | ||
| Q1 24 | -21.3% | -15.4% |
资本支出强度ASIXOFIX
| Q4 25 | 7.7% | 4.9% | ||
| Q3 25 | 7.1% | 4.8% | ||
| Q2 25 | 6.9% | 3.5% | ||
| Q1 25 | 9.0% | 3.5% | ||
| Q4 24 | 10.4% | 4.0% | ||
| Q3 24 | 7.7% | 2.7% | ||
| Q2 24 | 7.4% | 4.7% | ||
| Q1 24 | 10.5% | 5.6% |
现金转化率ASIXOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
